IGF-1 DES: The Complete Guide

IGF-1 DES — also called des(1-3)IGF-I or destripeptide-IGF-I — is native human IGF-I missing the first three N-terminal residues (Gly-Pro-Glu, "GPE"). The result is a 67-amino-acid peptide of ~7.4 kDa, three residues shorter than the 70-aa parent.

Unlike LR3, DES is naturally occurring. It was first isolated from bovine colostrum by Francis et al. 1988 (PMID 3390164), where it showed higher biological activity than intact IGF-I in chick embryo fibroblasts. Sara, Carlsson-Skwirut and colleagues at Karolinska independently identified the same truncation in human fetal brain (PMID 2574573); the cleaved tripeptide GPE itself, sometimes called "glypromate," is a distinct neuroactive peptide. Recombinant production in CHO cells was established by McKinnon et al. 1991 (PMID 1883485).

Why those three residues matter so much: the GPE tripeptide sits at the N-terminus of the IGF-I B domain — the principal binding determinant for the IGFBP family. Removing GPE guts IGFBP affinity while leaving IGF-1R binding largely intact (Bagley 1989, PMID 2730580). The free fraction available to the receptor dominates in vivo, and the apparent potency rises.

Regulatory status

• FDA, EMA: not approved. The only FDA-approved IGF-I product is mecasermin (Increlex), recombinant native rhIGF-I (NDA 021839) for severe primary IGF-I deficiency in pediatrics. Increlex is not DES.
• WADA 2026: prohibited at all times under S2.3 (Growth Factors and Growth Factor Modulators). The list covers "IGF-1 (mecasermin) and its analogues" — DES qualifies. Detection in human plasma is validated via LC-HRMS (Thomas 2017 PMID 28668757; Mongongu 2021 PMID 33587816). If you compete in a WADA-tested sport, DES is detectable.

DES is a full IGF-1R agonist. Receptor engagement is qualitatively identical to native IGF-I — same downstream cascades, same biology. The difference is kinetic, not pharmacodynamic.

DES binds IGF-1R extracellular α-subunits, drives tyrosine autophosphorylation of intracellular β-subunit kinase domains, and recruits IRS-1/2 adaptor proteins. From there the canonical IGF-1R cascades bifurcate: PI3K → AKT → mTORC1 (the "anabolic" axis — protein synthesis, ribosomal biogenesis, satellite-cell proliferation, GLUT4-mediated glucose uptake, AKT-mediated cell survival via FOXO/BAD phosphorylation), and RAS → RAF → MEK → ERK1/2 MAPK (mitogenesis, proliferation, differentiation). DES also cross-binds the insulin receptor at low affinity, same as native IGF-I — but because the higher free fraction puts more peptide on the receptor, the per-microgram hypoglycemic effect is greater for DES than for native IGF-I (Tomas 1997, PMID 9415072, in pigs and marmosets — the cleanest in-vivo "more potent per microgram" anchor).

What "site-localized" actually means

DES doesn't have a tissue-targeting motif. Like all IGF-I analogues, it diffuses freely from the injection site into circulation. The reason DES is treated as "local" in community practice is purely pharmacokinetic: with a circulating t½ on the order of minutes, the drug doesn't reach systemic steady-state distribution before clearance. A high concentration persists at and around the injection depot for the few minutes of receptor occupancy that drive downstream signaling. The honest framing is "transient peri-injection dominance before systemic dilution and clearance" — not molecular tissue targeting.

No GH/IGF-I feedback suppression

Because DES clears quickly, a typical SC injection doesn't produce sustained hypothalamic-pituitary suppression of endogenous GH or IGF-I. This is the key mechanistic difference vs LR3 for stack design: DES is in principle compatible with GHRH analogs and GHRPs (CJC-1295, ipamorelin, sermorelin) where LR3 is mechanistically discouraged.

LR3 and DES are both IGFBP-resistant IGF-1R agonists, but they're not two flavors of the same thing. They differ on the dimension that matters most for use-case design: half-life and distribution.

Feature	IGF-1 DES	IGF-1 LR3
Sequence vs native	Deletion of N-terminal GPE; 67 aa	Glu³→Arg³ + 13-aa N-terminal extension; 83 aa
Origin	Naturally occurring (bovine colostrum, fetal brain)	Engineered (CSIRO, ~1989–1992)
MW	~7.4 kDa	~9.2 kDa
IGFBP affinity	Very low (deletion removes IGFBP-binding handle)	Very low (Arg³ + N-extension disrupts contact surface)
Plasma half-life	Minutes-scale	20–30 hours
Distribution	Peri-injection dominant before clearance	Systemic — reaches steady state
Endogenous GH/IGF suppression	Minimal at typical doses	Significant (PMIDs 7561636, 9488001)
Stack with GH secretagogues	Plausible	Mechanistically discouraged
Community use case	Localized hypertrophy, post-workout into target muscle	Systemic anabolic, daily SC, whole-body

One-sentence summary: DES and LR3 are both IGFBP-resistant IGF-1R agonists; DES is short-acting and used because clearance is fast enough to keep most of the dose near the injection site, while LR3 is long-acting and used because the dose reaches and stays at every IGF-1R-expressing tissue in the body.

There's no human RCT of DES for hypertrophy or anti-aging. The published evidence base is biochemistry, animal pharmacology, and anti-doping detection.

The Australian CSIRO group (Ballard, Francis, Tomas, Read) produced the rat-anabolism / catabolic-state-rescue series across the early 1990s: founding paper Ballard 1987 (PMID 2962574), nitrogen balance and muscle protein metabolism in nitrogen-restricted rats (Tomas 1991, PMID 1999680), gut-resection growth enhancement (Lemmey 1991, PMID 1996625), reduced renal mass (Martin 1991, PMID 1928375), dexamethasone-treated rats (Tomas 1992, PMID 1371669), diabetic rats with growth restored without all the insulin-like effects (Tomas 1993, PMID 7683875). The cleanest in-vivo "more potent per microgram" anchor is Tomas 1997 (PMID 9415072) showing more potent and prolonged hypoglycemic action in pigs and marmosets.

The "10× more potent in vitro" claim that gets repeated traces to Ballard 1987 (PMID 2962574) and Carlsson-Skwirut 1989 (PMID 2469478). DES is approximately an order of magnitude more active per nanomolar in cell-based protein-synthesis assays where IGFBP binding sequesters intact IGF-I. That ratio applies to IGFBP-rich in-vitro assays specifically — the in-vivo ratio is closer to 2–3× per microgram (the rat/pig/marmoset literature). Stating "10× more potent" without the assay context overstates the case.

No human RCT establishes a DES dose for hypertrophy. The protocol below is community / vendor convention.

Parameter	Common Range
Dose per injection	20–100 µg
Frequency	1–2× daily on training days
Timing	Immediately pre- or post-workout, into or near the trained muscle
Cycle length	4–6 weeks on / 4–6 weeks off
Route	SC or IM (IM near target muscle is the community convention for the "site enhancement" effect)

The community pattern is to inject immediately around or post-workout, into or near the trained muscle, for whatever localized action the depot kinetics permit. The mechanistic premise (transient peri-injection dominance) is plausible. The human evidence base for site-specific muscle-fiber gain with DES is community reports only — no imaging, biopsy, or histology study has been published.

DES reconstitution diverges from LR3 at the solvent question. Most vendors describe DES as tolerant of bacteriostatic water at neutral pH — for a 1 mg vial in 1 mL BAC, that's 1 mg/mL (1000 µg/mL), so 1 unit on a U-100 syringe = 10 µg, and a 50 µg dose = 5 units. Some vendors recommend 0.6% acetic acid as a conservative default, which maintains solubility under storage conditions where some peptide chemistries can lose activity in neutral solution. If your vendor specifies acetic acid, use it.

Lyophilized vials are stable at room temperature short-term; refrigerate for longer. Reconstituted vials should be refrigerated and used within 14–21 days. For long storage, freeze single-use aliquots.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

No published human safety data for DES specifically. Everything below is mechanism-anchored, animal-anchored, or extrapolated from the Increlex label.

Hypoglycemia — the dominant acute risk

IGF-I cross-activates the insulin receptor at low affinity. For DES, the per-microgram hypoglycemic effect is greater than for native IGF-I (Tomas 1997, PMID 9415072) because the higher free fraction puts more peptide on the receptor. Onset is typically 30–90 min post-injection; can be delayed several hours. Symptoms run the standard insulin-class spectrum: tremor, sweating, tachycardia, hunger, confusion, visual changes; severe events progress to syncope, seizure, loss of consciousness.

Mitigations: dose with a carbohydrate-containing meal within 20 min (the FDA Increlex label requirement; defensible as a class precaution); have fast-acting glucose available; do not dose pre-bed; do not stack with insulin or insulin secretagogues.

Cancer-axis class concern

IGF-1R signaling is mitogenic and anti-apoptotic. Observational and Mendelian-randomization evidence supports a probable causal association between higher circulating IGF-I and incident colorectal cancer (Larsson 2020, PMID 32717139), with positive observational signals for prostate cancer (Travis 2016, PMID 26921328) and postmenopausal ER-positive breast cancer. Effect sizes per SD in the population are modest (HR ~1.07–1.30), but DES use produces a stimulus outside the physiological range. Active or prior cancer is a contraindication.

Other class concerns

• Localized tissue overgrowth or asymmetric hypertrophy — the intent of "site enhancement" is localized growth; the failure mode is when growth becomes disproportionate, distorts function, or affects the wrong tissue (subcutaneous fat fibrosis, fascial thickening, muscle-belly asymmetry).
• Cardiac and visceral hypertrophy with sustained dosing — class concern from rodent IGF-I studies (PMIDs 8023938, 7561636).
• Insulin resistance with chronic use — class effect, documented for rhGH and tesamorelin.
• Soft-tissue, cartilage, or acromegaly-like changes — mechanistically plausible by analogy (PMID 15523595, IGF-I mandibular enlargement in rats); not characterized in human DES data.
• Edema and sodium retention — IGF-I-axis class effect; less commonly reported with DES than with LR3 because total systemic exposure per dose is lower.

• Active or prior cancer — absolute. The conservative position for any IGF-1R agonist.
• Pre-cancerous conditions (known dysplasia, intraductal papillary neoplasms).
• Uncontrolled diabetes — hypoglycemia risk in combination with insulin or sulfonylureas.
• Active proliferative diabetic retinopathy — class concern from Increlex label.
• Pregnancy or lactation — no safety data.
• Pediatric use without specialist supervision — growth-plate and IGF-I axis interactions are specialist territory.
• Recent stroke or cardiac events — class caution for any anabolic stimulus.
• Concurrent insulin or insulin secretagogues — additive hypoglycemia.
• Athletes subject to anti-doping testing — do not use. WADA S2.3; detectable via LC-HRMS.

IGF-1 LR3 — same IGFBP escape strategy, opposite PK design. See the LR3-vs-DES table above.

MGF (mechano growth factor / IGF-1Ec) — both are IGF-I family members; the resemblance ends there. MGF is a splice variant of the IGF-I gene; the active species is hypothesized to be the cleaved 24-aa E-peptide acting via a non-IGF-1R mechanism. DES is a canonical IGF-1R agonist.

IGF-2. Separate gene product (~67 aa, similar size but unrelated sequence beyond the IGF-family fold). Binds IGF-2R preferentially. Not in clinical or community use as an injectable.

Insulin. Both can engage the insulin receptor and lower blood glucose. Insulin is far more potent at IR (DES binds at ~1/100th of insulin's affinity). The clinical hazard is interactive: don't stack DES with insulin or insulin secretagogues.

Mecasermin (Increlex). Recombinant native rhIGF-I, FDA-approved for severe primary IGF-I deficiency in pediatrics. DES is not Increlex. The truncated form is not an FDA-approved product.